TOPICS: Rituximab, anti cd 20 monoclinic antibody, non hodgkin lymphoma, waldenstrom macroglobulinemia, raynaud's phenomenon, thrombotic thrombocytopenic purpura, rheumatoid arthritis, multiple sclerosis, autoimmune hemolytic anemia, cll, progressive multifocal leukoencephalopathy, bevacizumab, monoclonal antibody, vegf, angiogenesis, colorectal cancer, renal cell carcinoma, non small cell lung cancer, wet macular degeneration, hemorrhage, impaired wound healing, blood clots, alemtuzumab, cd 52, cll, multiple sclerosis, cetuximab, panitumumab, egfr, stage IV colorectal cancer, wild type kras, head and neck cancer, rash, elevated lfts, diarrhea, trastuzumab, her2, her2+ breast cancer, gastric cancer, dilated cardiomyopathy
